The company remains "optimistic about Ninlaro and continue to investigate Ninlaro in patient populations across the continuum of multiple myeloma care".Original Article
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.